Formycon And Fresenius Kabi Receive FDA Approval For Fyb202/ Otulfitm
Sept 30 (Reuters) -FORMYCON AG FYB.DE:
AND FRESENIUS KABI RECEIVE FDA APPROVAL FOR FYB202/ OTULFITM(USTEKINUMAB-AAUZ)
TULFITMRECEIVED FDA APPROVAL FOR BOTH SUBCUTANEOUS AND INTRAVENOUS FORMULATIONS, TO TREAT SAME CONDITIONS AS STELARA®
APPROVAL REPRESENTS THIRD SUCCESSFUL FDA APPROVAL FOR A FORMYCON BIOSIMILAR, TWO OF THEM IN 2024
IN ACCORDANCE WITH PATENT SETTLEMENT BETWEEN FORMYCON, FRESENIUS KABI AND JOHNSON & JOHNSON, FRESENIUS KABI HAS RIGHT TO MARKET OTULFITM IN US NO LATER THAN FEBRUARY 22, 2025
OTULFITMRECEIVED FDA APPROVAL FOR BOTH SUBCUTANEOUS AND INTRAVENOUS FORMULATIONS, TO TREAT SAME CONDITIONS AS STELARA®
STELARA® GLOBAL SALES EXCEEDED USD 10 BILLION IN 2023
FYB202 SHOWS COMPARABLE EFFICACY TO STELARA® IN PSORIASIS
Source text for Eikon: ID:nEQ1ZDpvCa
Further company coverage: FYB.DE
(Gdansk Newsroom)
</body></html>Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
